Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation
Cutis · 01.06.2026 · 6 (117)
DOI: 10.12788/cutis.1406 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cutis, erschienen am 01.06.2026. Verfasst von Houriah Y Nukaly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Nukaly is from the Division of Experimental Medicine, McGill University Health Centre, Montréal, Québec, Canada. Drs. Srikakolapu and Elston are …. Hauptthemen laut MEDLINE: Adalimumab, Anti-Inflammatory Agents, Granuloma, Skin Diseases.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dr. Nukaly is from the Division of Experimental Medicine, McGill University Health Centre, Montréal, Québec, Canada. Drs. Srikakolapu and Elston are from the Department of Dermatology and Dermatologic Surgery, Medical U…
Zitieren
APA
Nukaly, H. Y., Srikakolapu, S., & Elston, D. M. (2026). Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation. Cutis, 6(117). https://doi.org/10.12788/cutis.1406
Vancouver
Nukaly HY, Srikakolapu S, Elston DM. Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation. Cutis. 2026;6(117). doi:10.12788/cutis.1406
BibTeX
@article{Nukaly2026,
author = {Nukaly, Houriah Y and Srikakolapu, Siddharth and Elston, Dirk M},
title = {Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation},
journal = {Cutis},
year = {2026},
volume = {6},
number = {117},
doi = {10.12788/cutis.1406}
}
EUVIMED